Trial
Data
| ProSaw® (For
Treatment of Prostate Enlargement (BPH) : Capsules) |
| This
Product is available in Ukraine under the name PROSTATOVID Capsule |
| The
mean volume of the enlarged prostate gland was recorded as 21.6 ± 3.89
cm cube before treatment and this was found reduced to 6.50 ± 1.03 cm cube
after thirty days treatment with ProSaw. There was a reduction in the severity
of the clinical signs from seven days after the initiation of the treatment. The
findings of this study indicate that the herbal drug ProSaw is very effective
in the management of BPH.
Prathaban,
S. and Balachandran, C. (2004). Clinical Report TNVAS University,Chennai |
SUMMARY
OF INTERNATIONAL CLINICAL TRIALS (DOUBLE
BLIND PLACEBO CONTROLLED) PROVING THE EFFICACY OF SAW PALMETTO EXTRACT
| Authors
& Journal | Improvement in urological
symptomatology (%difference over baseline) | Tolerability | | Emili
et. al, 1983 Urologia, 50, 1042 | Maximum and mean flow (+33,
+29), Decreased residual urine (-51) and day time and nocturnal frequency (-32,-50),
Reduction in strangury in 92% of cases. | Excellent | | Champault
et. al, 1984 Br. J. Clin. Pharmac. 18, 461. | Voiding rate (+50),
Reduction in residual urine (-42) and dysuria and nocturia (-46) | Excellent | | Tasca
et. al, 1985 Min. Urol. Nefr. 37, 87 | Maximum and mean flow
(+26, +61), Voided volume (+19), Reduction in day time and nocturnal frequency(-42,
-74) | Excellent | | Rece
smith et. al, 1986Br. J. Urol. 58, 36 | Urinary flow rate (+35),
Reduction in nocturnal frequency (-36),urgency (-32),hesitancy (-58), and terminal
dribbling (-37). | Good | | Mattei
et. al, 1988 Urologia 55, 547 | Reduction in residual urine(-59)
and day time and nocturnal frequency (-42, -67) | Excellent | | Descotes
et. al, 1995 clin. Drug Invest. 9, 291 | Maximum flow (+29),
Reduction in daytime and nocturnal frequency (-11,32) and dysuria (-31) | Excellent | | Univ.
Chicago Med. Cent. Dekalb Clinic,lllinois Urology 2001, 58; 960 | International
Prostate symptom Score decreased 4.4 Points as compared to 2.2 in placebo group | Excellent |
COMPARATIVE
EFFICACY AND SAFETY PROFILE OF PROSAW AND OTHER BPH TREATMENTS |
Parameter | Prazosin | Terazosin | Finasteride | Herbal
ProSaw | Mechanism
of action | Alpha Blocker | Alpha
Blocker | 5 Alpha Reductase inhibitor | Targetted
Multi-Pronged Actions including 5 Alpha Reductase inhibition, Antagonishing DHT
binding to receptors, Anti-oestrogenic, Anti-inflammatory, Diuretic and Anti-oxidant
for comprehensive control of BPH and quick symptomatic and long lasting relief. | Time
taken for showing symptomatic improvement | 30-90
days | 30-90 days | 180-360
days | 30-60 days | Effective
on swollen prostate | None | None | None | Reduces
the size of swollen prostate between 10% to 70%. | Safety
profile : major adverse effects | Low
safety profile: marked Hypotension, Hypersensitivity reactions, Headache, Dizziness,
Faintness, Tachycardia, Weight gain. | Low
safety profile: Marked Hypotension, and other postural symptoms, Hypersensitivity
reactions, Drowsiness, Dizziness, Blurred vision, Asthenia, Syncopal episodes,
Headache & Nausea. | Low safety
profile: Impotence, Decreased libido and semen volume, Hypersensitivity reactions. | High
safety profile: Favourable effect on libido. Stomach upset only, in rare cases. |
|
|
